Management of constipation in Parkinson’s disease

Bibliography

• de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol 2006;5:525-35
   PubMed Web of Science ®Google Scholar
• Den Oudsten BL, Van Heck GL, De Vries J. Quality of life and related concepts in Parkinson’s disease: a systematic review. Mov Disord 2007;22:1528-37
   PubMed Web of Science ®Google Scholar
• Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368-76
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 2010;25:704-9
   PubMed Web of Science ®Google Scholar
• Gonera EG, van’t Hof M, Berger HJ, et al. Symptoms and duration of the prodromal phase in Parkinson’s disease. Mov Disord 1997;12:871-6
   PubMed Web of Science ®Google Scholar
• Hawkes CH. The prodromal phase of sporadic Parkinson’s disease: does it exist and if so how long is it? Mov Disord 2008;23:1799-807
   PubMedGoogle Scholar
• Siderowf A, Stern MB. Preclinical diagnosis of Parkinson’s disease: are we there yet? Curr Neurol Neurosci Rep 2006;6:295-301
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007;22:1623-9
   PubMed Web of Science ®Google Scholar
• Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci 2002;14:223-36. discussion 2
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol 2003;2:107-16
   PubMed Web of Science ®Google Scholar
• Edwards LL, Pfeiffer RF, Quigley EM, et al. Gastrointestinal symptoms in Parkinson’s disease. Mov Disord 1991;6:151-6
   PubMed Web of Science ®Google Scholar
• Kaye J, Gage H, Kimber A, et al. Excess burden of constipation in Parkinson’s disease: a pilot study. Mov Disord 2006;21:1270-3
   PubMed Web of Science ®Google Scholar
• Siddiqui MF, Rast S, Lynn MJ, et al. Autonomic dysfunction in Parkinson’s disease: a comprehensive symptom survey. Parkinsonism Relat Disord 2002;8:277-84
   PubMed Web of Science ®Google Scholar
• Savica R, Carlin JM, Grossardt BR, et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 2009;73:1752-8
   PubMed Web of Science ®Google Scholar
• Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 2001;57:456-62
   PubMed Web of Science ®Google Scholar
• Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 2012;72:893-901
   PubMed Web of Science ®Google Scholar
• Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007;25:599-608
   PubMed Web of Science ®Google Scholar
• Caplan LH, Jacobson HG, Rubinstein BM, et al. Megacolon and Volvulus in Parkinson’s Disease. Radiology 1965;85:73-9
   PubMed Web of Science ®Google Scholar
• Cersosimo MG, Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord 2008;23:1065-75
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91
   PubMed Web of Science ®Google Scholar
• Probst A, Bloch A, Tolnay M. New insights into the pathology of Parkinson’s disease: does the peripheral autonomic system become central? Eur J Neurol 2008;15(Suppl 1):1-4
   PubMedGoogle Scholar
• Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197-211
   PubMed Web of Science ®Google Scholar
• Del Tredici K, Rub U, De Vos RA, et al. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002;61:413-26
   PubMed Web of Science ®Google Scholar
• Braak H, Sastre M, Bohl JR, et al. Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 2007;113:421-9
   PubMed Web of Science ®Google Scholar
• Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119:689-702
   PubMed Web of Science ®Google Scholar
• Gold A, Turkalp ZT, Munoz DG. Enteric alpha-synuclein expression is increased in Parkinson’s disease but not Alzheimer’s disease. Mov Disord 2013;28:237-40
   PubMed Web of Science ®Google Scholar
• Lebouvier T, Neunlist M, Bruley des Varannes S, et al. Colonic biopsies to assess the neuropathology of Parkinson’s disease and its relationship with symptoms. PLoS One 2010;5:e12728
   PubMed Web of Science ®Google Scholar
• Pouclet H, Lebouvier T, Coron E, et al. A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson’s disease. Neurobiol Dis 2012;45:305-9
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Takahashi H, Ohama E, et al. Parkinson’s disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 1990;79:581-3
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Takahashi H, Takeda S, et al. Parkinson’s disease: the presence of Lewy bodies in Auerbach’s and Meissner’s plexuses. Acta Neuropathol 1988;76:217-21
   PubMed Web of Science ®Google Scholar
• Singaram C, Ashraf W, Gaumnitz EA, et al. Dopaminergic defect of enteric nervous system in Parkinson’s disease patients with chronic constipation. Lancet 1995;346:861-4
   PubMed Web of Science ®Google Scholar
• Hilton D, Stephens M, Kirk L, et al. Accumulation of alpha-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease. Acta Neuropathol 2014;127:235-41
   PubMed Web of Science ®Google Scholar
• Shannon KM, Keshavarzian A, Mutlu E, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease. Mov Disord 2012;27:709-15
   PubMed Web of Science ®Google Scholar
• Cersosimo MG, Benarroch EE. Pathological correlates of gastrointestinal dysfunction in Parkinson’s disease. Neurobiol Dis 2012;46:559-64
   PubMed Web of Science ®Google Scholar
• Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease: frequency and pathophysiology. Neurology 1992;42:726-32
   PubMed Web of Science ®Google Scholar
• Edwards LL, Quigley EM, Harned RK, et al. Characterization of swallowing and defecation in Parkinson’s disease. Am J Gastroenterol 1994;89:15-25
   PubMed Web of Science ®Google Scholar
• Jost WH, Schimrigk K. Constipation in Parkinson’s disease. Klin Wochenschr 1991;69:906-9
   PubMedGoogle Scholar
• Jost WH, Schimrigk K. The effect of cisapride on delayed colonic transit time in patients with idiopathic Parkinson’s disease. Wien Klin Wochenschr 1994;106:673-6
   PubMed Web of Science ®Google Scholar
• Jost WH, Schrank B. Defecatory disorders in de novo Parkinsonians–colonic transit and electromyogram of the external anal sphincter. Wien Klin Wochenschr 1998;110:535-7
   PubMed Web of Science ®Google Scholar
• Ashraf W, Pfeiffer RF, Quigley EM. Anorectal manometry in the assessment of anorectal function in Parkinson’s disease: a comparison with chronic idiopathic constipation. Mov Disord 1994;9:655-63
   PubMed Web of Science ®Google Scholar
• Bassotti G, Maggio D, Battaglia E, et al. Manometric investigation of anorectal function in early and late stage Parkinson’s disease. J Neurol Neurosurg Psychiatry 2000;68:768-70
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Odaka T, Uchiyama T, et al. Colonic transit time and rectoanal videomanometry in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2003;74:268-72
   PubMed Web of Science ®Google Scholar
• Wang CP, Sung WH, Wang CC, et al. Early recognition of pelvic floor dyssynergia and colorectal assessment in Parkinson’s disease associated with bowel dysfunction. Colorectal Dis 2013;15:e130-7
   Web of Science ®Google Scholar
• Ashraf W, Wszolek ZK, Pfeiffer RF, et al. Anorectal function in fluctuating (on-off) Parkinson’s disease: evaluation by combined anorectal manometry and electromyography. Mov Disord 1995;10:650-7
   PubMed Web of Science ®Google Scholar
• Edwards LL, Quigley EM, Harned RK, et al. Defecatory function in Parkinson’s disease: response to apomorphine. Ann Neurol 1993;33:490-3
   PubMed Web of Science ®Google Scholar
• Ueki A, Otsuka M. Life style risks of Parkinson’s disease: association between decreased water intake and constipation. J Neurol 2004;251(Suppl 7):vII18-23
   PubMedGoogle Scholar
• Andrews CN, Storr M. The pathophysiology of chronic constipation. Can J Gastroenterol 2011;25(Suppl B):16B-21B
   PubMedGoogle Scholar
• Gray JR. What is chronic constipation? Definition and diagnosis. Can J Gastroenterol 2011;25(Suppl B):7B-10B
   Google Scholar
• Zeino Z, Sisson G, Bjarnason I. Adverse effects of drugs on small intestine and colon. Best Pract Res Clin Gastroenterol 2010;24:133-41
   PubMed Web of Science ®Google Scholar
• Gage H, Kaye J, Kimber A, et al. Correlates of constipation in people with Parkinson’s. Parkinsonism Relat Disord 2011;17:106-11
   PubMed Web of Science ®Google Scholar
• Jost WH. Gastrointestinal motility problems in patients with Parkinson’s disease. Effects of antiparkinsonian treatment and guidelines for management. Drugs Aging 1997;10:249-58
   PubMed Web of Science ®Google Scholar
• American Gastroenterological Association. Bharucha AE, Dorn SD, et al. American Gastroenterological Association medical position statement on constipation. Gastroenterology 2013;144:211-17
   PubMed Web of Science ®Google Scholar
• Astarloa R, Mena MA, Sanchez V, et al. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol 1992;15:375-80
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010;74:924-31
   PubMed Web of Science ®Google Scholar
• Bove A, Bellini M, Battaglia E, et al. Consensus statement AIGO/SICCR diagnosis and treatment of chronic constipation and obstructed defecation (part II: treatment). World J Gastroenterol 2012;18:4994-5013
   PubMed Web of Science ®Google Scholar
• Lindberg G, Hamid SS, Malfertheiner P, et al. World Gastroenterology Organisation global guideline: constipation–a global perspective. J Clin Gastroenterol 2011;45:483-7
   PubMed Web of Science ®Google Scholar
• de Oliveira EP, Burini RC. The impact of physical exercise on the gastrointestinal tract. Curr Opin Clin Nutr Metab Care 2009;12:533-8
   PubMed Web of Science ®Google Scholar
• Simren M. Physical activity and the gastrointestinal tract. Eur J Gastroenterol Hepatol 2002;14:1053-6
   PubMed Web of Science ®Google Scholar
• Salat-Foix D, Suchowersky O. The management of gastrointestinal symptoms in Parkinson’s disease. Expert Rev Neurother 2012;12:239-48
   PubMed Web of Science ®Google Scholar
• Ashraf W, Pfeiffer RF, Park F, et al. Constipation in Parkinson’s disease: objective assessment and response to psyllium. Mov Disord 1997;12:946-51
   PubMed Web of Science ®Google Scholar
• Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov Disord 2007;22:1239-44
   PubMed Web of Science ®Google Scholar
• Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 2011;26(Suppl 3):S42-80
   PubMed Web of Science ®Google Scholar
• Coggrave M, Norton C, Cody JD. Management of faecal incontinence and constipation in adults with central neurological diseases. Cochrane Database Syst Rev 2014;1:CD002115
   Google Scholar
• McKeage K, Plosker GL, Siddiqui MA. Lubiprostone. Drugs 2006;66:873-9
   PubMed Web of Science ®Google Scholar
• Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006;290:G942-7
   PubMed Web of Science ®Google Scholar
• Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004;287:C1173-83
   PubMed Web of Science ®Google Scholar
• Chan WW, Mashimo H. Lubiprostone increases small intestinal smooth muscle contractions through a prostaglandin E receptor 1 (EP1)-mediated pathway. J Neurogastroenterol Motil 2013;19:312-18
   PubMed Web of Science ®Google Scholar
• Hooks SBIII, Rutland TJ, Di Palma JA. Lubiprostone neither decreases gastric and small-bowel transit time nor improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled study. Gastrointest Endosc 2009;70:942-6
   PubMed Web of Science ®Google Scholar
• Whitehead WE, Palsson OS, Gangarosa L, et al. Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. Neurogastroenterol Motil 2011;23:944-e400
   PubMed Web of Science ®Google Scholar
• Sweetser S, Busciglio IA, Camilleri M, et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol 2009;296:G295-301
   PubMed Web of Science ®Google Scholar
• Ao M, Venkatasubramanian J, Boonkaewwan C, et al. Lubiprostone activates Cl- secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84. Dig Dis Sci 2011;56:339-51
   PubMed Web of Science ®Google Scholar
• Jakab RL, Collaco AM, Ameen NA. Lubiprostone targets prostanoid signaling and promotes ion transporter trafficking, mucus exocytosis, and contractility. Dig Dis Sci 2012;57:2826-45
   PubMed Web of Science ®Google Scholar
• Lacy BE, Levy LC. Lubiprostone: a chloride channel activator. J Clin Gastroenterol 2007;41:345-51
   PubMed Web of Science ®Google Scholar
• Cuppoletti J, Blikslager AT, Chakrabarti J, et al. Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors. BMC Pharmacol 2012;12:3
   PubMedGoogle Scholar
• De Lisle RC. Lubiprostone stimulates small intestinal mucin release. BMC Gastroenterol 2012;12:156
   PubMed Web of Science ®Google Scholar
• Chey WD, Drossman DA, Johanson JF, et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2012;35:587-99
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Johanson JF, Parkman HP, et al. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci 2011;56:2639-45
   PubMed Web of Science ®Google Scholar
• Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome–results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329-41
   PubMed Web of Science ®Google Scholar
• Shah E, Kim S, Chong K, et al. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med 2012;125:381-93
   PubMed Web of Science ®Google Scholar
• Ondo WG, Kenney C, Sullivan K, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology 2012;78:1650-4
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rey MV, Pavy-Le Traon A, et al. Emerging drugs for autonomic dysfunction in Parkinson’s disease. Expert Opin Emerg Drugs 2013;18:39-53
   PubMed Web of Science ®Google Scholar
• Soykan I, Sarosiek I, Shifflett J, et al. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson’s disease. Mov Disord 1997;12:952-7
   PubMed Web of Science ®Google Scholar
• Bondon-Guitton E, Perez-Lloret S, Bagheri H, et al. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord 2011;26:2226-31
   PubMed Web of Science ®Google Scholar
• Jost WH, Schimrigk K. Long-term results with cisapride in Parkinson’s disease. Mov Disord 1997;12:423-5
   PubMed Web of Science ®Google Scholar
• Morgan JC, Sethi KD. Tegaserod in constipation associated with Parkinson disease. Clin Neuropharmacol 2007;30:52-4
   PubMed Web of Science ®Google Scholar
• Sullivan KL, Staffetti JF, Hauser RA, et al. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson’s disease. Mov Disord 2006;21:115-16
   PubMed Web of Science ®Google Scholar
• Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005;20:680-6
   PubMed Web of Science ®Google Scholar
• Cassani E, Privitera G, Pezzoli G, et al. Use of probiotics for the treatment of constipation in Parkinson’s disease patients. Minerva Gastroenterol Dietol 2011;57:117-21
   PubMedGoogle Scholar
• Miller LE, Ouwehand AC. Probiotic supplementation decreases intestinal transit time: meta-analysis of randomized controlled trials. World J Gastroenterol 2013;19:4718-25
   PubMed Web of Science ®Google Scholar
• Arnold C. The pros and cons of probiotics. Lancet Infect Dis 2013;13:571-2
   PubMed Web of Science ®Google Scholar
• Rothstein RD, Friedenberg FK. Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation. Expert Opin Pharmacother 2013;14:2125-32
   PubMed Web of Science ®Google Scholar
• Shailubhai K, Comiskey S, Foss JA, et al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci 2013;58:2580-6
   PubMed Web of Science ®Google Scholar
• Shin A, Camilleri M, Kolar G, et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 2014;39:239-53
   PubMed Web of Science ®Google Scholar
• Wong BS, Camilleri M. Elobixibat for the treatment of constipation. Expert Opin Investig Drugs 2013;22:277-84
   PubMed Web of Science ®Google Scholar
• Tateno F, Sakakibara R, Yokoi Y, et al. Levodopa ameliorated anorectal constipation in de novo Parkinson’s disease: the QL-GAT study. Parkinsonism Relat Disord 2011;17:662-6
   PubMed Web of Science ®Google Scholar
• Rao SS, Valestin J, Brown CK, et al. Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial. Am J Gastroenterol 2010;105:890-6
   PubMed Web of Science ®Google Scholar
• Chiu CM, Wang CP, Sung WH, et al. Functional magnetic stimulation in constipation associated with Parkinson’s disease. J Rehabil Med 2009;41:1085-9
   PubMed Web of Science ®Google Scholar
• Albanese A, Brisinda G, Bentivoglio AR, et al. Treatment of outlet obstruction constipation in Parkinson’s disease with botulinum neurotoxin A. Am J Gastroenterol 2003;98:1439-40
   PubMed Web of Science ®Google Scholar
• Cadeddu F, Bentivoglio AR, Brandara F, et al. Outlet type constipation in Parkinson’s disease: results of botulinum toxin treatment. Aliment Pharmacol Ther 2005;22:997-1003
   PubMed Web of Science ®Google Scholar
• Markland AD, Palsson O, Goode PS, et al. Association of low dietary intake of fiber and liquids with constipation: evidence from the National Health and Nutrition Examination Survey. Am J Gastroenterol 2013;108:796-803
   PubMed Web of Science ®Google Scholar